A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations
Recruiting · Phase 4 · NCT06585241
Conditions: SARS-CoV-2
At a glance
- Research payments reported, 2025
- $381,615
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 1,144
About the trial
- Sponsor
- ModernaTX, Inc.
- Tested
- mRNA-1273 Variant-containing Formulation (biological)
- Dates
- Started 2024-09-09; completion 2026-12-31
- Results posted
- Not yet
The purpose of this study is to investigate the immunogenicity and safety of mRNA COVID-19 variant-containing vaccine formulations against the vaccine-matched variants and newly emerged variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
From ClinicalTrials.gov, last updated 2026-03-27. Full record, eligibility and contacts (opens in a new tab)
Industry funding
ModernaTX, Inc. reported $381,615 in research payments for this study in 2025 (8 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Kimball A. Johnson, MD Internal Medicine · Atlanta, GA
- Jessica C. Mccoun, M.D. Anesthesiology · Rome, GA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Cenexel Iresearch LLC $333,438
- Atlanta Center for Medical Res $48,177
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.